Milestone Scientific Launches CompuFlo® Advisor Program to Accelerate Commercial Adoption and Drive Utilization Growth in Select MAC Jurisdictions; Plans National Expansion

Rhea-AI Summary

Milestone Scientific (NYSE: MLSS) launched the CompuFlo Advisor Program on February 1, 2026 to accelerate commercial adoption, increase recurring disposable revenue, and generate clinical data aimed at improving Medicare reimbursement for CPT 0777T.

The program targets high-volume interventional pain and anesthesia practices in select MAC jurisdictions (Novitas, First Coast, Noridian, Palmetto) with a planned 1,000–2,000 case submissions in the initial six months and a commercial infrastructure intended to support phased national expansion.

Positive

• 1,000–2,000 targeted case submissions in initial six months
• Launch commenced Feb 1, 2026, marking program start
• Initial focus on four MAC jurisdictions: Novitas, First Coast, Noridian, Palmetto
• Deployed commercial infrastructure to support phased national expansion
• Engaged reimbursement experts including Evelyn Gittinger, CPC and NMS

Negative

• Initial rollout limited to select MAC jurisdictions, constraining near-term scope
• Program success hinges on achieving targeted 1,000–2,000 submissions in six months
• Outcome depends on transition of CPT 0777T from Category III to Category I status

Key Figures

Program start date: February 1, 2026 Target case submissions: 1,000–2,000 cases Initial phase duration: Six months +3 more

6 metrics

Program start date February 1, 2026 CompuFlo Advisor Program commencement

Target case submissions 1,000–2,000 cases Initial six-month phase for clinical/reimbursement data

Initial phase duration Six months First phase of CompuFlo Advisor Program

CPT code 0777T Targeted for transition from Category III to Category I

CPT category (current) Category III Current status of CPT code 0777T

CPT category (target) Category I Planned transition for CPT code 0777T

Market Reality Check

Price: $0.2578 Vol: Volume 76,010 is below th...

low vol

$0.2578 Last Close

Volume Volume 76,010 is below the 20-day average of 173,215, indicating muted pre-news trading interest. low

Technical Price at $0.2576 is trading below the $0.53 200-day moving average, reflecting a longer-term downtrend.

Peers on Argus

MLSS was down 2.46% pre-news while key peers were mixed: NEPH +4.62%, POCI +0.91...

MLSS was down 2.46% pre-news while key peers were mixed: NEPH +4.62%, POCI +0.91%, RVP +0.35%, HBIO -2.77%, NXGL -1.63%. No peers appeared in the momentum scanner, suggesting stock-specific factors rather than a sector-wide move.

Historical Context

5 past events · Latest: Jan 06 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 06	Dental program launch	Positive	-4.3%	Launched The Wand Ambassador Program to drive dental adoption and demos.
Nov 13	Q3 2025 results	Neutral	+6.0%	Reported stable revenue with reduced operating expenses and modest growth.
Nov 13	Earnings call notice	Neutral	+6.0%	Scheduled Q3 2025 results and business update conference call.
Oct 14	Operational update	Positive	-1.7%	Outlined progress under new CEO, cost cuts and CompuFlo growth plans.
Oct 14	NYSE notice	Negative	-1.7%	Disclosed NYSE American non‑compliance and need for a plan to regain it.

Pattern Detected

Positive strategic updates have sometimes coincided with negative short-term reactions, while mixed/earnings-related news has seen more favorable trading responses.

Recent Company History

Over the past several months, MLSS has focused on cost controls, operational restructuring, and new commercial programs. A Jan 6, 2026 dental Ambassador Program launch and an Oct 14, 2025 operational update under new leadership outlined growth and recurring revenue initiatives, yet shares fell after both. In contrast, Q3 2025-11-13 financial results with stable revenue and reduced expenses saw a +6.03% move. The NYSE American non‑compliance notice on Oct 14, 2025 aligned with a negative reaction, highlighting ongoing listing and balance sheet overhangs.

Market Pulse Summary

This announcement details a structured commercial and reimbursement strategy around CompuFlo, target...

Analysis

This announcement details a structured commercial and reimbursement strategy around CompuFlo, targeting 1,000–2,000 documented cases in an initial six‑month phase to help move CPT code 0777T from Category III to Category I. It builds on earlier programs aimed at recurring revenue and adoption in dental and medical markets. Investors may monitor execution in the selected MAC jurisdictions, progress toward CPT reclassification, and how these efforts interact with prior cost reductions and NYSE American compliance plans.

Key Terms

medicare administrative contractor, mac, cpt code 0777t, key opinion leaders

4 terms

medicare administrative contractor regulatory

"targets high-volume interventional pain and anesthesia practices within key Medicare Administrative Contractor (MAC) jurisdictions"

A Medicare Administrative Contractor is a private company hired to handle billing, payments, provider enrollment, and routine audits for Medicare in a specific region, acting like a local claims processor for a large government health plan. Investors care because these contractors influence how quickly and accurately healthcare providers get reimbursed, which affects providers’ cash flow, revenue timing and audit risk—key drivers of financial stability for companies that rely on Medicare payments.

mac regulatory

"within key Medicare Administrative Contractor (MAC) jurisdictions, including Novitas, First Coast, Noridian, and Palmetto"

A MAC (material adverse change) is a contract clause that lets one party walk away or renegotiate a deal if the other party’s business suffers a significant, lasting decline. Think of it like an insurance policy for buyers: it protects them from unforeseen events that materially reduce the target’s value or future earnings, and investors watch for MACs because their presence and wording affect deal risk, timing, and potential losses.

cpt code 0777t regulatory

"roadmap to transition CPT® code 0777T from Category III to Category I status"

CPT code 0777T is a temporary Category III billing code used to identify and track a specific, newer medical procedure or service for reimbursement and data collection. Think of it as a provisional product barcode for a new clinical technique: it helps insurers, hospitals and doctors record how often the service is used and whether they will pay for it. Investors watch such codes because they signal emerging treatments whose insurance coverage and billing rates can directly affect adoption, provider revenue and market potential.

key opinion leaders technical

"By engaging Key Opinion Leaders (KOLs) to generate a targeted 1,000–2,000 case submissions"

Key opinion leaders are respected experts—often physicians, scientists, or industry specialists—whose published work, clinical experience, or public commentary shapes professional and public views about a medical product, treatment or technology. Investors watch them because their endorsements, criticisms or research can influence regulatory reviews, clinical adoption and sales prospects; think of them as trusted referees whose call can sway public confidence and market demand.

AI-generated analysis. Not financial advice.

ROSELAND, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide objective, pressure-guided precision, today announced the launch of the CompuFlo® Advisor Program. This strategic initiative is designed to drive mainstream commercial adoption, increase recurring disposable revenue, and generate the clinical data necessary to optimize long-term Medicare reimbursement rates.

The program, which commenced on February 1, 2026, targets high-volume interventional pain and anesthesia practices within key Medicare Administrative Contractor (MAC) jurisdictions, including Novitas, First Coast, Noridian, and Palmetto. These jurisdictions represent a strategic first phase of execution, with infrastructure designed to support phased expansion across additional MAC regions throughout the United States. By engaging Key Opinion Leaders (KOLs) to generate a targeted 1,000–2,000 case submissions in the initial six-month phase, Milestone is executing a structured clinical and reimbursement roadmap to transition CPT® code 0777T from Category III to Category I status, that could enhance commercial adoption and long-term revenue visibility.

To ensure the program delivers a scalable recurring revenue model, Milestone has deployed a robust commercial infrastructure designed to support national expansion. The Company has also engaged industry veterans, including Evelyn Gittinger, CPC, and Neuro Management Solutions (NMS), to provide real-time claims support, documentation guidance, and payer advocacy.

"The Advisor Program is a key strategic initiative for Milestone Scientific this year," stated Eric Hines, CEO of Milestone Scientific. "We have moved beyond simply placing devices to building a comprehensive commercial ecosystem. We are deploying a 'white glove' support infrastructure, including veteran consultants and a dedicated provider hotline, to support our physicians through every step of the reimbursement process. With favorable unit economics and a scalable model, we believe establishing reimbursement with this initial cohort will unlock a recurring revenue flywheel that can be rapidly expanded to hundreds of physicians nationwide."

About Milestone Scientific Inc.
Milestone Scientific Inc. (MLSS) is a technology-focused medical research and development company that patents, designs, and develops innovative injection technologies and instruments for medical and dental applications. Milestone Scientific’s computer-controlled systems are designed to make injections precise, efficient and increase the overall patient comfort and safety. Their proprietary DPS Dynamic Pressure Sensing Technology^® instruments is the platform to advance the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions of subcutaneous drug delivery, including local anesthetic. To learn more, view the MLSS brand video or visit milestonescientific.com.

Safe Harbor Statement

This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2024. The forward-looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason. Coding and payment decisions are determined solely by providers and payers based on applicable laws and policies. Any potential Category I designation is determined solely by the American Medical Association and is not guaranteed. Providers remain responsible for compliance with all applicable billing, coding, and regulatory requirements. Forward-looking case submission expectations, reimbursement targets, and revenue estimates referenced herein are based on current program enrollment, advisor commitments, and historical payer activity, and are subject to change based on clinical scheduling, payer processing timelines, regulatory developments, and other factors. There can be no assurance that Category I designation, targeted reimbursement levels, or projected revenue levels will be achieved.

Contact:         

HAYDEN IR:
James Carbonara
(646)-755-7412
james@haydenir.com

Brett Maas
(646) 536-7331
brett@haydenir.com 

FAQ

What is the CompuFlo Advisor Program launched by Milestone Scientific (MLSS) on Feb 1, 2026?

The CompuFlo Advisor Program is a commercial and clinical initiative to boost adoption and reimbursement for CompuFlo. According to the company, it targets high-volume pain and anesthesia practices to generate clinical cases and payer documentation to support CPT 0777T reimbursement.

How many case submissions does Milestone (MLSS) plan to generate in the program's initial six-month phase?

Milestone plans to generate between 1,000 and 2,000 case submissions in six months. According to the company, these targeted submissions are intended to produce clinical and reimbursement data to support a CPT 0777T code transition.

Which MAC jurisdictions does Milestone Scientific (MLSS) target for the initial CompuFlo Advisor rollout?

The initial rollout targets Novitas, First Coast, Noridian, and Palmetto MAC jurisdictions. According to the company, these regions were selected as a strategic first phase to build infrastructure for phased national expansion.

What commercial support has Milestone (MLSS) deployed for physicians participating in the CompuFlo Advisor Program?

Milestone has deployed a 'white glove' support infrastructure including a provider hotline and veteran consultants. According to the company, it engaged Evelyn Gittinger, CPC, and Neuro Management Solutions for claims support and payer advocacy.

How could the CompuFlo Advisor Program affect Medicare reimbursement for CPT 0777T for Milestone (MLSS)?

The program aims to generate data to transition CPT 0777T from Category III to Category I status. According to the company, successful submissions could improve long-term Medicare reimbursement and enhance revenue visibility for the device.

Will the CompuFlo Advisor Program expand nationally beyond initial MAC jurisdictions for Milestone (MLSS)?

Yes, the program is designed for phased national expansion after the initial phase. According to the company, a scalable commercial infrastructure has been deployed to support broader rollout to additional MAC regions across the U.S.